Safety and Efficacy of Intensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent Ischemic Stroke or Transient Ischemic Attack: Rationale and Design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) Trial (ISRCTN47823388)
Restricted accessOtherFirst published online October, 2015
Safety and Efficacy of Intensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent Ischemic Stroke or Transient Ischemic Attack: Rationale and Design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) Trial (ISRCTN47823388)
The risk of recurrence following a stroke or transient ischemic attack is high, especially immediately after the event.
Hypothesis
Because two antiplatelet agents are superior to one in patients with non-cardioembolic events, more intensive treatment might be even more effective.
Sample size estimates
The sample size of 4100 patients will allow a shift to less recurrence, and less severe recurrence, to be detected (odds ratio 0·68) with 90% power at 5% significance.
Methods and design
Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (ISRCTN47823388) is comparing the safety and efficacy of intensive (combined aspirin, clopidogrel, and dipyridamole) vs. guideline antiplatelet therapy, both given for one-month. This international collaborative parallel-group prospective randomized open-label blinded-end-point phase III trial plans to recruit 4100 patients with acute ischemic stroke or transient ischemic attack. Randomization and data collection are performed over a secure Internet site with real-time data validation and concealment of allocation. Outcomes, serious adverse events, and neuroimaging are adjudicated centrally with blinding to treatment allocation.
Study outcome
The primary outcome is stroke recurrence and its severity (‘ordinal recurrence’ based on modified Rankin Scale) at 90 days, with masked assessment centrally by telephone. Secondary outcomes include vascular events, functional measures (disability, mood, cognition, quality of life), and safety (bleeding, death, serious adverse events).
Discussion
The trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One-third of patients presented with a transient ischemic attack.
RothwellPMGilesMFChandrathevaA. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (express study): a prospective population-based sequential comparison. Lancet Neurol2007; 370:1432–42.
2.
LavalleePCMeseguerEAbboudH. A transient ischaemic attach clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol2007; 6:953–60.
3.
JohnsonSCLeiraECHansenMDAdamsHPJ. Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann Neurol2003; 54:439–44.
4.
JohnsonSCEastonJD. Are patients with acutely recovered cerebral ischemia more unstable?Stroke2003; 34:2446–50.
5.
PATS Collaborating Group.Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J1995; 108:710–7.
6.
PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001; 358:1033–41.
7.
RashidPLeonardi-BeeJBathP. Blood pressure reduction and the secondary prevention of stroke and other vascular events: a systematic review. Stroke2003; 34:2741–9.
8.
Heart Protection Study Collaborative Group.Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet2004; 363:757–67.
9.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med2006; 355:549–59.
10.
Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM, for the Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet2004; 363:915–24.
11.
EAFT (European Atrial Fibrillation Trial) Study Group.Secondary prevention in non-rheumatic atrial fibrillation after TIA or minor stroke. Lancet1993; 342:1255–62.
12.
DienerHCConnollySJEzekowitzMD. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol2010; 9:1157–63.
13.
HankeyGJPatelMRStevensSR. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol2012; 11:315–22.
14.
EastonJDLopesRDBahitMC. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol2012; 11:503–11.
15.
FarrellBGodwinJRichardsSWarlowC. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry1991; 54:1044–54.
16.
The Dutch TIA Trial Study Group.A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med1991; 325:1261–6.
17.
International Stroke Trial Collaborative Group.The international stroke trial (ist); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet1997; 349:1569–81.
18.
CAST (Chinese Acute Stroke Trial) Collaborative Group.Cast: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet1997; 349:1641–9.
19.
DienerHCCunhaLForbesCSiveniusJSmetsPLowenthalA. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci1996; 143:1–13.
20.
Leonardi-BeeJBathPMBousserMG. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke2005; 36:162–8.
21.
The ESPRIT Study Group.Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet2006; 367:1665–73.
22.
HalkesPHGrayLJBathPM. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry2008; 79:1218–23.
23.
WangYWangYZhaoX. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med2013; 369:11–9.
24.
KennedyJHillMDRyckborstK. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol2007; 6:961–9.
25.
DenglerRDienerHCSchwartzA. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (early trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol2010; 9:159–66.
26.
BathPMCottonDMartinRH. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: profess subgroup analysis. Stroke2010; 41:732–8.
27.
GeeganageCMDienerH-CAlgraA. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack. Stroke2012; 43:1058–66.
28.
WongKSLWangYLengX. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation2013; 128:1656–66.
29.
MichelsonADCattaneoMEikelboomJW. Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost2005; 3:1309–11.
30.
Siller-MatulaJSchrorKWojtaJHuberK. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost2007; 97:385–93.
31.
SerebruanyVCheralaGWilliamsC. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of ‘resistance’. Am Heart J2009; 158:925–32.
32.
BhattDLFoxKAAWerner HackeCB. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354:1706–17.
33.
DienerHCBogousslavskyJBrassLM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): randomised, double-blind, placebo-controlled trial. Lancet2004; 364:331–7.
34.
BathPMW. Role of aspirin in match. Lancet2004; 364:1662.
35.
ZhaoLBathPHeptinstallS. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol2001; 134:353–8.
36.
ScholzTZhaoLTemmlerUBathPHeptinstallSLoscheW. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets2002; 13:401–6.
37.
ZhaoLBathPMWFoxS. The effects of GPII–IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin2003; 19:178–86.
38.
ZhaoLFletcherSWeaverC. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and lecokyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost2005; 93:527–34.
39.
ZhaoLGrayLJLeonardi-BeeJWeaverCSHeptinstallSBathPM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets2006; 17:100–4.
40.
SpriggNGrayLJEnglandT. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS ONE2008; 3:e2852.
41.
WillmotMZhaoLHeptinstallSBathPMW. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis2004; 13:138–40.
42.
BathPRobsonKWoodhouseLSpriggNDineenRPocockS. Statistical analysis plan for the ‘triple antiplatelets for reducing dependency after ischaemic stroke’ (TARDIS) trial. Int J Stroke2015; 10:449–51.
43.
BamfordJSandercockPDennisMBurnJWarlowC. Classification and natural-history of clinically identifiable subtypes of cerebral infarction. Lancet1991; 337:1521–6.
44.
AdamsHPDavisPHLeiraEC. Baseline NIH stroke scale score strongly predicts outcome after stroke. A report of the Trial of Org 10 172 in Acute Stroke Treatment (TOAST). Neurology1999; 53:126–31.
45.
WardlawJMSellarR. A simple practical classification of cerebral infarcts on ct and its interobserver reliability. Am J Neuroradiol1994; 15:1933–9.
46.
BarberPADemchukAMZhangJJBuchanAMGroupAS. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet2000; 355:1670–4.
47.
SandercockPWardlawJMLindleyRI. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet2012; 379:2352–63.
48.
BathPWoodhouseLScuttP. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet2015; 385:617–28.
49.
BamfordJSandercockPDennisMBurnJWarlowC. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet1991; 337:1521–6.
50.
WeirCJLeesKR. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Stat Med2003; 22:705–26.
51.
Anonymous. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet1997; 349:1569–81.
52.
YusufSFoxKAATognoniG. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. NEJM2001; 345:494–502.
53.
DienerHCCunhaLForbesCSiveniusJSmetsPLowenthalA. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci1996; 143:1–13.
54.
StewartKWaltersMDawsonJ. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90). Heart2011; 97:585–6.
55.
HallasJDallMAndriesA. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ2006; 333:726.
56.
BrooksR. Euroqol: the current state of play. Health Policy (New York)1996; 37:53–72.
57.
ZungWWK. A self-rating depression scale. Arch Gen Psychiatry1965; 12:63–70.
58.
BathPMWGeeganageCMGrayLJCollierTPocockS. Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials. Stroke2008; 39:2817–23.
59.
WeaverCSLeonardi-BeeJBath-HextallFJBathPMW. Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome. Stroke2004; 35:1216–24.
60.
The Optimising Analysis of Stroke Trials (OAST) Collaboration.Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke2008; 3:78–84.
61.
The Optimising Analysis of Stroke Trials (OAST) Collaboration.Should stroke trials adjust functional outcome for baseline prognostic factors?Stroke2009; 40:888–94.
